デフォルト表紙
市場調査レポート
商品コード
1383614

膀胱がん治療および診断市場- 世界の産業規模、シェア、動向、機会、予測、2018年~2028年、治療別、診断別、がんタイプ別、地域別、競合

Bladder Cancer Therapeutics and Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Therapeutics, by Diagnostics , by Cancer Type, By Region, and Competition

出版日: | 発行: TechSci Research | ページ情報: 英文 174 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.08円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

膀胱がん治療および診断市場- 世界の産業規模、シェア、動向、機会、予測、2018年~2028年、治療別、診断別、がんタイプ別、地域別、競合
出版日: 2023年10月03日
発行: TechSci Research
ページ情報: 英文 174 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の膀胱がん治療および診断市場は、予測期間中に目覚ましい成長を遂げると予測されています。

膀胱の内壁にある健康な細胞(最も多いのは尿路上皮細胞)が変化して制御不能に膨張し、腫瘍として知られる塊を形成すると、膀胱がんが発症します。腎盂、尿管、尿道はすべて尿路上皮細胞で覆われています。尿路上皮がんのもう一つの形態は、上部尿路上皮がんと呼ばれ、腎盂と尿管に発生するがんです。このがんは、このガイダンスで膀胱がんについて述べたような方法で治療されることが多いです。腫瘍には良性と悪性があります。悪性とは、がん性腫瘍が発生し、身体の異なる部位に転移する能力を指します。腫瘍が良性の場合は、大きくなることはあっても転移することはありません。良性の膀胱腫瘍が発生することはまれです。膀胱がんの世界の罹患率の上昇、特に高齢化が大きな原動力となっています。膀胱がんの症例数の増加は、より多くの患者を生み出し、治療および診断の需要を促進します。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の膀胱がん治療および診断市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 治療別(化学療法、免疫療法、その他の治療薬)
    • 診断別(膀胱鏡、膀胱超音波、尿検査、その他の診断薬)
    • がんタイプ別(移行細胞膀胱がん、扁平上皮膀胱がん、その他のがんタイプ)
    • 地域別
    • 企業別(2022年)
  • 市場マップ

第6章 アジア太平洋地域の膀胱がん治療および診断市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 治療別
    • 診断別
    • がんタイプ別
    • 国別
  • アジア太平洋地域国別分析
    • 中国
    • インド
    • オーストラリア
    • 日本
    • 韓国

第7章 欧州の膀胱がん治療および診断市場展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • 治療別
    • 診断別
    • がんタイプ別
    • 国別
  • 欧州国別分析
    • フランス
    • ドイツ
    • スペイン
    • イタリア
    • 英国

第8章 北米の膀胱がん治療および診断市場展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • 治療別
    • 診断別
    • がんタイプ別
    • 国別
  • 北米国別分析
    • 米国
    • メキシコ
    • カナダ

第9章 南米の膀胱がん治療および診断市場展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • 治療別
    • 診断別
    • がんタイプ別
    • 国別
  • 南米:国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの膀胱がん治療および診断市場展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • 治療別
    • 診断別
    • がんタイプ別
    • 国別
  • MEA:国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 製品上市
  • 合併と買収

第13章 世界の膀胱がん治療および診断市場:SWOT分析

第14章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第15章 PESTLE分析

第16章 競合情勢

  • Ameritech Diagnostic Reagent(Jiaxing)Co., Ltd
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials(In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • Bristol-Myers Squibb Company
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials(In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • Eli Lilly and Company
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials(In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • F. Hoffmann-La Roche Ltd
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials(In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • GlaxoSmithKline PLC
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials(In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • Novartis International AG
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials(In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • Pfizer Inc.
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials(In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • Abbott Inc.
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials(In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • Endo Pharmaceuticals Inc.
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials(In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • Johnson & Johnson(Janssen Pharmaceutical)
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials(In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • Merck & Co. Inc
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials(In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • Astellas Pharma Inc.
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials(In case of listed companies)
    • Recent Developments
    • SWOT Analysis

第17章 戦略的提言

第18章 調査会社・免責事項

目次
Product Code: 18742

Global Bladder Cancer Therapeutics and Diagnostics Market is anticipated to witness an impressive growth in the forecast period. When healthy cells in the bladder lining most frequently urothelial cells change and expand uncontrollably, forming a mass known as a tumor, bladder cancer develops. The renal pelvis, ureters, and urethra are all lined with urothelial cells. Another form of urothelial cancer, known as upper tract urothelial carcinoma, is cancer that originates in the renal pelvis and ureters. It is often treated in a manner like that discussed in this guidance for bladder cancer. A tumor may be benign or malignant. Malignant refers to the ability of a cancerous tumor to develop and metastasize to different body regions. If a tumor is benign, it can enlarge but won't spread. Rarely do benign bladder tumors occur. A rising global incidence of bladder cancer, especially in aging populations, has been a significant driver. The growing number of bladder cancer cases creates a larger patient pool, driving demand for diagnostics and therapeutics.

Continuous improvements in diagnostic techniques, including enhanced imaging technologies, urine-based biomarker tests, and genetic profiling, have improved early detection and diagnosis of bladder cancer, thereby increasing the demand for diagnostics. The development of novel therapeutic approaches, such as immunotherapies (e.g., checkpoint inhibitors) and targeted therapies, has expanded treatment options and improved outcomes for bladder cancer patients. These innovations drive market growth. Ongoing clinical trials and research initiatives to explore new treatments, combination therapies, and personalized medicine approaches create opportunities for market expansion. The aging global population is more susceptible to bladder cancer. As the elderly population grows, the prevalence of bladder cancer is expected to increase, leading to higher demand for therapeutics and diagnostics.

Key Market Drivers

Increasing Innovative Therapies

Innovative therapies in cancer therapeutics and diagnostics have transformed the way cancer is diagnosed and treated. These groundbreaking approaches offer new hope for patients and have the potential to improve outcomes while reducing side effects. Immunotherapy harnesses the body's immune system to target and destroy cancer cells. Immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and cancer vaccines are among the most promising approaches. These therapies have shown remarkable results in various cancers, including melanoma, lung cancer, and leukemia. Precision medicine, also known as personalized medicine, tailors cancer treatment based on a patient's genetic, genomic, and molecular profile. Targeted therapies, such as tyrosine kinase inhibitors and PARP inhibitors, are designed to specifically target the genetic mutations or abnormalities driving a patient's cancer. Gene therapy involves the introduction or modification of genes to treat or prevent diseases, including cancer. CAR-T cell therapy is a prime example, where a patient's T cells are genetically engineered to target cancer cells with precision. Cancer vaccines stimulate the immune system to recognize and attack cancer cells. Therapeutic cancer vaccines aim to treat existing cancer, while preventive vaccines, like the HPV vaccine, prevent certain cancers from developing. Liquid biopsies involve analyzing blood, urine, or other bodily fluids to detect cancer-specific biomarkers, including circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs). These tests are minimally invasive and can provide insights into a patient's cancer status, treatment response, and minimal residual disease. Innovations in radiation therapy, such as intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), and proton therapy, allow for highly targeted radiation delivery, minimizing damage to healthy tissue.

Nanotechnology is used to develop nanoscale drug delivery systems that can target cancer cells more precisely, enhance drug delivery efficiency, and reduce side effects. AI and machine learning algorithms are applied to medical imaging data to assist radiologists and pathologists in detecting and diagnosing cancer more accurately. AI can analyze large datasets, identify patterns, and aid in treatment planning. Onco-genomics involves the genomic profiling of tumors to identify specific genetic mutations and alterations. This information guides treatment decisions and helps identify potential therapeutic targets. Epigenetic therapies focus on modifying gene expression through changes in DNA methylation and histone modifications. These therapies aim to reverse or silence cancer-promoting genes. Building on CAR-T cell therapy, CAR-NK cell therapy uses natural killer (NK) cells that have been genetically engineered to target cancer cells. It offers potential advantages, including reduced side effects. Patient-derived organoids are three-dimensional cultures of cancer cells that mimic the patient's tumor. They are used for drug testing, personalized treatment selection, and studying cancer biology. This factor will help in the development of Global Bladder Cancer Therapeutics and Diagnostics Market.

Growing Aging Population

Cancer is predominantly a disease of aging, with the risk of developing cancer rising significantly as people grow older. Many types of cancer, such as breast, prostate, lung, and colorectal cancer, are more common in older individuals. As the population ages, the overall incidence of cancer increases. This leads to a greater number of cancer cases, necessitating a higher demand for diagnostic tests, treatments, and ongoing monitoring. Older cancer patients often have complex healthcare needs due to the presence of multiple chronic conditions or comorbidities. This complexity can drive demand for comprehensive diagnostics and specialized treatments tailored to the individual. Early cancer detection is crucial for better outcomes. The aging population may benefit from increased screening and diagnostic efforts to identify cancer at an earlier, more treatable stage. Older patients may have unique treatment challenges, including tolerance to therapies, potential drug interactions with other medications, and age-related physiological changes. These factors necessitate a more tailored approach to cancer therapeutics.

The field of geriatric oncology focuses on addressing the specific needs of older cancer patients. It aims to develop age-appropriate treatment regimens and supportive care measures, leading to improved treatment outcomes. With improvements in cancer treatments, more older individuals are living as cancer survivors. Survivorship care, which includes ongoing monitoring and management of late effects and cancer recurrence, is essential for this population. Older cancer patients may benefit from palliative and supportive care services aimed at improving their quality of life, managing symptoms, and providing emotional and psychological support. Public health campaigns and initiatives often target older populations to raise awareness about cancer risk factors and encourage regular screenings, contributing to early detection and timely treatment. Healthcare systems need to be prepared to address the unique needs of an aging population, including access to cancer care, geriatric assessments, and supportive services. This factor will accelerate the demand of Global Bladder Cancer Therapeutics and Diagnostics Market.

Rising Bladder Cancer Incidence

Bladder cancer is a global health concern characterized by the abnormal growth of cells in the bladder lining. The demographic shift towards an aging population is a significant driver of bladder cancer incidence. As individuals age, their risk of developing bladder cancer increases. The older population is more likely to experience this disease, leading to a higher overall incidence rate. Smoking remains one of the most well-established risk factors for bladder cancer. The carcinogens found in tobacco smoke can accumulate in the bladder, leading to cellular damage over time. Despite awareness campaigns, tobacco use persists, contributing to the incidence of bladder cancer. Certain occupations, such as those involving exposure to industrial chemicals and carcinogens, have been linked to an increased risk of bladder cancer. Workers in industries like chemical manufacturing, textile, and printing are particularly vulnerable. Environmental pollutants, including contaminated drinking water sources, exposure to industrial waste, and agricultural chemicals, have been associated with bladder cancer. Prolonged exposure to these substances can elevate the risk of developing the disease. Bladder cancer is more common in men than in women. This gender disparity contributes to the higher overall incidence rate, as men are generally at greater risk due to biological and behavioral factors. Genetic predisposition can play a role in bladder cancer incidence. Individuals with a family history of the disease may have an increased susceptibility.

The rising incidence of bladder cancer places a substantial burden on healthcare systems worldwide. The diagnosis, treatment, and long-term care of bladder cancer patients require significant resources. The economic costs associated with bladder cancer are substantial, encompassing healthcare expenses, lost productivity, and the financial burden on individuals and families affected by the disease. Bladder cancer can profoundly affect the quality of life of those diagnosed. Patients often undergo invasive treatments, such as surgery, chemotherapy, and radiation therapy, which can lead to physical and emotional challenges. Although bladder cancer is often treatable when detected early, the rise in incidence may also lead to increased mortality rates if timely diagnosis and effective treatments are not accessible. Encouraging smoking cessation programs and policies can have a significant impact on reducing bladder cancer incidence. Providing resources and support for individuals looking to quit smoking is essential. Promoting regular health check-ups and cancer screenings can lead to the early detection of bladder cancer, improving the chances of successful treatment. Strengthening environmental regulations and monitoring efforts to reduce pollution and chemical exposure is vital for preventing environmentally induced bladder cancer. This factor will pace up the demand of Global Bladder Cancer Therapeutics and Diagnostics Market

Key Market Challenges

High Treatment Costs

The financial burden associated with bladder cancer diagnosis and treatment affects not only patients but also healthcare systems and society. The diagnostic process for bladder cancer often includes multiple procedures, such as cystoscopy, imaging (CT scans, MRI), urine tests, and potentially invasive biopsies. These diagnostic tests and procedures can accumulate substantial costs. Bladder cancer treatment options vary depending on the stage and type of cancer. Treatments may include surgery, chemotherapy, radiation therapy, immunotherapy, or a combination of these approaches. Each of these treatment modalities carries its own cost implications. Surgical procedures for bladder cancer, whether open or minimally invasive, can be expensive. Costs include surgeon fees, operating room expenses, anesthesia, and hospitalization. Immunotherapy and targeted therapies, while offering promising outcomes, can be expensive due to the high cost of drug development and administration. Some of these treatments are administered over an extended period. External beam radiation therapy and brachytherapy are common treatments for bladder cancer. The cost of radiation therapy includes the use of specialized equipment and personnel. The cost of chemotherapy drugs, as well as the monitoring and management of side effects, can be a significant financial burden on patients and healthcare systems. Bladder cancer patients often require long-term surveillance and monitoring for recurrence. This includes regular check-ups, imaging, and urine tests, which can add to the overall cost of care.

Health Disparities

Limited access to healthcare services, including early cancer detection and timely treatment, is a significant driver of health disparities. Individuals with limited access to medical facilities are often diagnosed at more advanced stages of bladder cancer, leading to poorer outcomes. Disparities exist in the utilization of cancer screening and early detection services. Some populations, due to socioeconomic factors or lack of awareness, may not undergo recommended screenings, resulting in delayed diagnosis. Socioeconomic factors, such as income, education, and employment status, play a significant role in health disparities. Individuals with lower socioeconomic status may have less access to healthcare resources and face barriers to receiving timely and high-quality bladder cancer care. Disparities in access to healthcare services are often more pronounced in rural or underserved areas. Patients in these regions may face longer travel distances to reach specialized cancer centers, resulting in delays in diagnosis and treatment initiation. Racial and ethnic minorities may experience disparities in bladder cancer incidence, treatment options, and outcomes. Factors such as cultural beliefs, language barriers, and discrimination can contribute to these disparities. Lack of health insurance or underinsurance can lead to disparities in access to bladder cancer diagnostic tests, treatments, and follow-up care. Uninsured or underinsured individuals may delay seeking care due to financial concerns.

Key Market Trends

Minimally Invasive Surgical Techniques

Minimally invasive surgical techniques, such as laparoscopic and robotic-assisted surgery, often result in smaller incisions, less pain, and faster recovery times compared to open surgery. This leads to improved post-operative outcomes and a better quality of life for bladder cancer patients. Minimally invasive procedures typically require shorter hospital stays, reducing healthcare costs and freeing up hospital resources for other patients. Robotic-assisted surgery allows for precise removal of bladder tumors while preserving healthy tissue. This is especially important for patients with non-muscle-invasive bladder cancer (NMIBC) where tumor recurrence is a concern. Smaller incisions and reduced tissue trauma lower the risk of surgical site infections, which is a significant concern in open surgeries. Patients who undergo minimally invasive procedures often experience quicker recoveries, enabling them to return to their daily activities and work sooner. Minimally invasive techniques are associated with less pain and discomfort during the post-operative period, reducing the need for heavy pain medications. Smaller incisions result in less visible scarring, which can be particularly important for patients' body image and self-esteem. Laparoscopic and robotic systems provide surgeons with enhanced visualization of the surgical site, allowing for more precise tumor removal and reduced damage to healthy tissue.

Segmental Insights

Therapeutics Insights

In 2022, the Global Bladder Cancer Therapeutics and Diagnostics Market largest share was held by Chemotherapy segment and is predicted to continue expanding over the coming years. Chemotherapy is used in various stages of bladder cancer, including before surgery (neoadjuvant chemotherapy), after surgery (adjuvant chemotherapy), and for advanced or metastatic disease. Its versatility in treating different stages of the disease makes it a widely used therapeutic option. Chemotherapy has demonstrated effectiveness in treating bladder cancer, particularly for patients with muscle-invasive disease or metastatic disease. It can help shrink tumours, reduce the risk of recurrence, and prolong survival. In many cases, chemotherapy is considered a standard of care for certain types and stages of bladder cancer. Clinical guidelines often recommend its use in specific situations, further solidifying its role in treatment.

Diagnostics Insights

In 2022, the Global Bladder Cancer Therapeutics and Diagnostics Market dominated by Cystoscopy segment and is predicted to continue expanding over the coming years. Cystoscopy is considered one of the most accurate methods for diagnosing bladder cancer. It involves the direct visualization of the inside of the bladder using a thin, flexible tube equipped with a camera. This allows healthcare professionals to identify abnormal growths or tumours with precision. Cystoscopy has been a standard diagnostic procedure for bladder cancer for many years. Its long history of use has made it a trusted method among healthcare providers. Cystoscopy provides real-time visual confirmation of the presence of tumours, allowing for immediate biopsy or removal if necessary. This immediate feedback can guide treatment decisions. During cystoscopy, tissue samples (biopsies) can be taken for pathological examination, aiding in cancer staging and determining the aggressiveness of the tumour.

Cancer Type Insights

In 2022, the Global Bladder Cancer Therapeutics and Diagnostics Market largest share was held by Transitional Cell Bladder Cancer segment in the forecast period and is predicted to continue expanding over the coming years. Transitional cell carcinoma is the most common histological subtype of bladder cancer, accounting for most bladder cancer cases worldwide. Its high prevalence naturally results in a significant share of the market. Given its prevalence, a substantial portion of research and development efforts in the field of bladder cancer therapeutics and diagnostics has been dedicated to transitional cell carcinoma. This focus has led to the development of targeted treatments and diagnostic methods specific to this subtype. Many clinical trials for bladder cancer therapies and diagnostics are designed to include patients with transitional cell carcinoma. This ensures a sizable patient population for testing new drugs, treatments, and diagnostic tools. Due to its prevalence, there is a wide range of therapeutic options available for transitional cell bladder cancer, including surgery, chemotherapy, immunotherapy, and targeted therapies. The diversity of treatment options drives market activity.

Regional Insights

The North America region dominates the Global Bladder Cancer Therapeutics and Diagnostics Market in 2022. North America, particularly the United States and Canada, boasts a well-developed healthcare infrastructure, including top-tier medical facilities, research institutions, and pharmaceutical companies. This infrastructure supports the development, testing, and adoption of advanced bladder cancer therapeutics and diagnostics. Many clinical trials for bladder cancer therapeutics and diagnostics are conducted in North America. The presence of a large patient population, experienced healthcare professionals, and regulatory frameworks conducive to clinical research make the region attractive for conducting trials and testing new therapies. North America has access to significant financial resources, including venture capital and private equity funding. This financial support facilitates the development and commercialization of novel bladder cancer treatments and diagnostics.

Key Market Players

Ameritech Diagnostic Reagent (Jiaxing)Co., Ltd

Bristol-Myers Squibb Company

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

GlaxoSmithKline PLC

Novartis International AG

Pfizer Inc.

Abbott Inc.

Endo Pharmaceuticals Inc.

Johnson & Johnson (Janssen Pharmaceutical)

Merck & Co. Inc

Astellas Pharma Inc.

Report Scope:

In this report, the Global Bladder Cancer Therapeutics and Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bladder Cancer Therapeutics and Diagnostics Market, By Therapeutics:

  • Chemotherapy
  • Immunotherapy
  • Other Therapeutics

Bladder Cancer Therapeutics and Diagnostics Market, By Diagnostics:

  • Cystoscopy
  • Bladder Ultrasound
  • Urinalysis
  • Other Diagnostics

Bladder Cancer Therapeutics and Diagnostics Market, By Cancer Type:

  • Transitional Cell Bladder Cancer
  • Squamous Cell Bladder Cancer
  • Other Cancer Types

Global Bladder Cancer Therapeutics and Diagnostics Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Bladder Cancer Therapeutics and Diagnostics Market.

Available Customizations:

  • Global Bladder Cancer Therapeutics and Diagnostics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bladder Cancer Therapeutics and Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapeutics (Chemotherapy, Immunotherapy, Other Therapeutics)
    • 5.2.2. By Diagnostics (Cystoscopy, Bladder Ultrasound, Urinalysis, Other Diagnostics)
    • 5.2.3. By Cancer Type (Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer, Other Cancer Types)
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Market Map

6. Asia Pacific Bladder Cancer Therapeutics and Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapeutics
    • 6.2.2. By Diagnostics
    • 6.2.3. By Cancer Type
    • 6.2.4. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Bladder Cancer Therapeutics and Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapeutics
        • 6.3.1.2.2. By Diagnostics
        • 6.3.1.2.3. By Cancer Type
    • 6.3.2. India Bladder Cancer Therapeutics and Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapeutics
        • 6.3.2.2.2. By Diagnostics
        • 6.3.2.2.3. By Cancer Type
    • 6.3.3. Australia Bladder Cancer Therapeutics and Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapeutics
        • 6.3.3.2.2. By Diagnostics
        • 6.3.3.2.3. By Cancer Type
    • 6.3.4. Japan Bladder Cancer Therapeutics and Diagnostics Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Therapeutics
        • 6.3.4.2.2. By Diagnostics
        • 6.3.4.2.3. By Cancer Type
    • 6.3.5. South Korea Bladder Cancer Therapeutics and Diagnostics Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Therapeutics
        • 6.3.5.2.2. By Diagnostics
        • 6.3.5.2.3. By Cancer Type

7. Europe Bladder Cancer Therapeutics and Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapeutics
    • 7.2.2. By Diagnostics
    • 7.2.3. By Cancer Type
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Bladder Cancer Therapeutics and Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapeutics
        • 7.3.1.2.2. By Diagnostics
        • 7.3.1.2.3. By Cancer Type
    • 7.3.2. Germany Bladder Cancer Therapeutics and Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapeutics
        • 7.3.2.2.2. By Diagnostics
        • 7.3.2.2.3. By Cancer Type
    • 7.3.3. Spain Bladder Cancer Therapeutics and Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapeutics
        • 7.3.3.2.2. By Diagnostics
        • 7.3.3.2.3. By Cancer Type
    • 7.3.4. Italy Bladder Cancer Therapeutics and Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapeutics
        • 7.3.4.2.2. By Diagnostics
        • 7.3.4.2.3. By Cancer Type
    • 7.3.5. United Kingdom Bladder Cancer Therapeutics and Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapeutics
        • 7.3.5.2.2. By Diagnostics
        • 7.3.5.2.3. By Cancer Type

8. North America Bladder Cancer Therapeutics and Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapeutics
    • 8.2.2. By Diagnostics
    • 8.2.3. By Cancer Type
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Bladder Cancer Therapeutics and Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapeutics
        • 8.3.1.2.2. By Diagnostics
        • 8.3.1.2.3. By Cancer Type
    • 8.3.2. Mexico Bladder Cancer Therapeutics and Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapeutics
        • 8.3.2.2.2. By Diagnostics
        • 8.3.2.2.3. By Cancer Type
    • 8.3.3. Canada Bladder Cancer Therapeutics and Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapeutics
        • 8.3.3.2.2. By Diagnostics
        • 8.3.3.2.3. By Cancer Type

9. South America Bladder Cancer Therapeutics and Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapeutics
    • 9.2.2. By Diagnostics
    • 9.2.3. By Cancer Type
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Bladder Cancer Therapeutics and Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapeutics
        • 9.3.1.2.2. By Diagnostics
        • 9.3.1.2.3. By Cancer Type
    • 9.3.2. Argentina Bladder Cancer Therapeutics and Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapeutics
        • 9.3.2.2.2. By Diagnostics
        • 9.3.2.2.3. By Cancer Type
    • 9.3.3. Colombia Bladder Cancer Therapeutics and Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Application

10. Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapeutics
    • 10.2.2. By Diagnostics
    • 10.2.3. By Cancer Type
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Bladder Cancer Therapeutics and Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapeutics
        • 10.3.1.2.2. By Diagnostics
        • 10.3.1.2.3. By Cancer Type
    • 10.3.2. Saudi Arabia Bladder Cancer Therapeutics and Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapeutics
        • 10.3.2.2.2. By Diagnostics
        • 10.3.2.2.3. By Cancer Type
    • 10.3.3. UAE Bladder Cancer Therapeutics and Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapeutics
        • 10.3.3.2.2. By Diagnostics
        • 10.3.3.2.3. By Cancer Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Bladder Cancer Therapeutics and Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. Ameritech Diagnostic Reagent (Jiaxing)Co., Ltd
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. Bristol-Myers Squibb Company
    • 16.2.1. Business Overview
    • 16.2.2. Company Snapshot
    • 16.2.3. Products & Services
    • 16.2.4. Financials (In case of listed companies)
    • 16.2.5. Recent Developments
    • 16.2.6. SWOT Analysis
  • 16.3. Eli Lilly and Company
    • 16.3.1. Business Overview
    • 16.3.2. Company Snapshot
    • 16.3.3. Products & Services
    • 16.3.4. Financials (In case of listed companies)
    • 16.3.5. Recent Developments
    • 16.3.6. SWOT Analysis
  • 16.4. F. Hoffmann-La Roche Ltd
    • 16.4.1. Business Overview
    • 16.4.2. Company Snapshot
    • 16.4.3. Products & Services
    • 16.4.4. Financials (In case of listed companies)
    • 16.4.5. Recent Developments
    • 16.4.6. SWOT Analysis
  • 16.5. GlaxoSmithKline PLC
    • 16.5.1. Business Overview
    • 16.5.2. Company Snapshot
    • 16.5.3. Products & Services
    • 16.5.4. Financials (In case of listed companies)
    • 16.5.5. Recent Developments
    • 16.5.6. SWOT Analysis
  • 16.6. Novartis International AG
    • 16.6.1. Business Overview
    • 16.6.2. Company Snapshot
    • 16.6.3. Products & Services
    • 16.6.4. Financials (In case of listed companies)
    • 16.6.5. Recent Developments
    • 16.6.6. SWOT Analysis
  • 16.7. Pfizer Inc.
    • 16.7.1. Business Overview
    • 16.7.2. Company Snapshot
    • 16.7.3. Products & Services
    • 16.7.4. Financials (In case of listed companies)
    • 16.7.5. Recent Developments
    • 16.7.6. SWOT Analysis
  • 16.8. Abbott Inc.
    • 16.8.1. Business Overview
    • 16.8.2. Company Snapshot
    • 16.8.3. Products & Services
    • 16.8.4. Financials (In case of listed companies)
    • 16.8.5. Recent Developments
    • 16.8.6. SWOT Analysis
  • 16.9. Endo Pharmaceuticals Inc.
    • 16.9.1. Business Overview
    • 16.9.2. Company Snapshot
    • 16.9.3. Products & Services
    • 16.9.4. Financials (In case of listed companies)
    • 16.9.5. Recent Developments
    • 16.9.6. SWOT Analysis
  • 16.10. Johnson & Johnson (Janssen Pharmaceutical)
    • 16.10.1. Business Overview
    • 16.10.2. Company Snapshot
    • 16.10.3. Products & Services
    • 16.10.4. Financials (In case of listed companies)
    • 16.10.5. Recent Developments
    • 16.10.6. SWOT Analysis
  • 16.11. Merck & Co. Inc
    • 16.11.1. Business Overview
    • 16.11.2. Company Snapshot
    • 16.11.3. Products & Services
    • 16.11.4. Financials (In case of listed companies)
    • 16.11.5. Recent Developments
    • 16.11.6. SWOT Analysis
  • 16.12. Astellas Pharma Inc.
    • 16.12.1. Business Overview
    • 16.12.2. Company Snapshot
    • 16.12.3. Products & Services
    • 16.12.4. Financials (In case of listed companies)
    • 16.12.5. Recent Developments
    • 16.12.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer